Monoclonal antibody | |
---|---|
Type | Bi-specific T-cell engager |
Source | Human |
Target | DLL3 and CD3 |
Clinical data | |
Trade names | Imdelltra |
Other names | AMG757; AMG-757, tarlatamab-dlle |
License data |
|
Routes of administration | Intravenous |
Drug class | Antineoplastic |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C4664H7139N1259O1454S34 |
Molar mass | 105202.82 g·mol−1 |
Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extended-scale small cell lung cancer. [1] It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3. [1]
The most common adverse reactions include cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, and constipation, anemia and nausea. [2]
It was approved for medical use in the United States in May 2024. [2] [3]
Tarlatamab is indicated for the treatment of adults with extensive stage small cell lung cancer with disease progression on or after platinum-based chemotherapy. [1] [2]
The prescribing information for tarlatamab includes a boxed warning for serious or life-threatening cytokine release syndrome (CRS) and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS). [1]
The most common adverse reactions include cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, and constipation, anemia and nausea. [2] The most common grade 3 or 4 laboratory abnormalities include decreased lymphocytes, decreased sodium, increased uric acid, decreased total neutrophils, decreased hemoglobin, increased activated partial thromboplastin time, and decreased potassium. [2]
Efficacy was evaluated in 99 participants with relapsed/refractory extensive stage small cell lung cancer with disease progression following platinum-based chemotherapy enrolled in DeLLphi-301 [NCT05060016], an open-label, multicenter, multi-cohort study. [2] Participants with symptomatic brain metastases, interstitial lung disease or non-infectious pneumonitis, and active immunodeficiency were excluded. [2] Participants received tarlatamab until disease progression or unacceptable toxicity. [2]
The FDA granted the application for tarlatamab priority review, breakthrough therapy, and orphan drug designations. [2]
Tarlatamab is the international nonproprietary name [4] and the United States Adopted Name. [5]